BR112014017656A2 - composto, composição farmacêutica, e, uso de um composto - Google Patents

composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BR112014017656A2
BR112014017656A2 BR112014017656A BR112014017656A BR112014017656A2 BR 112014017656 A2 BR112014017656 A2 BR 112014017656A2 BR 112014017656 A BR112014017656 A BR 112014017656A BR 112014017656 A BR112014017656 A BR 112014017656A BR 112014017656 A2 BR112014017656 A2 BR 112014017656A2
Authority
BR
Brazil
Prior art keywords
compound
pharmaceutical composition
diabetes
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
BR112014017656A
Other languages
English (en)
Inventor
Namiki Hidenori
Matsumoto Koji
Hoshino Madoka
Yamanoi Shigeo
Ochiai Yuichi
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BR112014017656A2 publication Critical patent/BR112014017656A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

1 / 1 resumo “composto, composiã‡ãƒo farmacãšutica, e, uso de um composto” sã£o providos compostos tendo uma excelente atividade hipoglicãªmica e uma excelente atividade protetora para uma cã©lula  ou o pã¢ncreas, ou um sal farmaceuticamente aceitã¡veis dos mesmos; e uma composiã§ã£o farmacãªutica tendo um excelente efeito terapãªutico e/ou um excelente efeito profilã¡tico na diabetes do tipo 1, diabetes do tipo 2, e similares, em que o aumento no nã­vel de glicose no sangue ã© induzido pelo metabolismo anormal de glicose. um composto representado pela fã³rmula (i) ou um sal farmaceuticamente aceitã¡vel do mesmo.
BR112014017656A 2012-01-18 2013-01-17 composto, composição farmacêutica, e, uso de um composto BR112014017656A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012007840 2012-01-18
PCT/JP2013/050710 WO2013108800A1 (ja) 2012-01-18 2013-01-17 置換フェニルアゾール誘導体

Publications (1)

Publication Number Publication Date
BR112014017656A2 true BR112014017656A2 (pt) 2017-06-27

Family

ID=48799224

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014017656A BR112014017656A2 (pt) 2012-01-18 2013-01-17 composto, composição farmacêutica, e, uso de um composto

Country Status (21)

Country Link
US (3) US9233958B2 (pt)
EP (2) EP2805941B1 (pt)
JP (2) JP6104181B2 (pt)
KR (1) KR20140113688A (pt)
CN (1) CN104159892A (pt)
AU (1) AU2013210394A1 (pt)
BR (1) BR112014017656A2 (pt)
CA (1) CA2861847A1 (pt)
CO (1) CO7020920A2 (pt)
ES (2) ES2640667T3 (pt)
HK (2) HK1220448A1 (pt)
IL (1) IL233682A0 (pt)
IN (1) IN2014MN01442A (pt)
MX (1) MX2014008790A (pt)
NZ (1) NZ627303A (pt)
PH (1) PH12014501646A1 (pt)
RU (1) RU2014133738A (pt)
SG (1) SG11201404026SA (pt)
TW (1) TWI551590B (pt)
WO (1) WO2013108800A1 (pt)
ZA (1) ZA201405108B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014008790A (es) 2012-01-18 2014-10-13 Daiichi Sankyo Co Ltd Derivado de fenilazol sustituido.
JP2017119628A (ja) * 2014-05-09 2017-07-06 日産化学工業株式会社 置換アゾール化合物及び糖尿病治療薬
WO2017104782A1 (ja) * 2015-12-17 2017-06-22 第一三共株式会社 オキサジアゾール化合物の製造方法
EP3766879A1 (en) * 2019-07-19 2021-01-20 Basf Se Pesticidal pyrazole derivatives
CN111388471B (zh) * 2020-03-03 2021-01-12 牡丹江医学院 一种治疗胆囊炎的药物及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0029974D0 (en) * 2000-12-08 2001-01-24 Glaxo Group Ltd Chemical compounds
EP1711491A1 (en) 2003-12-24 2006-10-18 Prosidion Limited Heterocyclic derivatives as gpcr receptor agonists
RU2006145872A (ru) * 2004-05-25 2008-06-27 Метаболекс, Инк. (Us) Замещенные триазолы в качестве модуляторов ppar и способы их получения
NZ564759A (en) 2005-06-30 2011-08-26 Prosidion Ltd GPCR agonists
EP1907383A1 (en) 2005-06-30 2008-04-09 Prosidion Limited Gpcr agonists
EP1931660B1 (en) * 2005-09-29 2012-08-01 Sanofi Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
BRPI0710839A2 (pt) * 2006-04-06 2011-08-23 Prosidion Ltd agonistas heterocìclicos de gpcr
GB0606913D0 (en) * 2006-04-06 2006-05-17 Prosidion Ltd Compounds
KR20100033419A (ko) * 2007-07-19 2010-03-29 메타볼렉스, 인코포레이티드 당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
KR101536021B1 (ko) 2007-10-16 2015-07-10 다이이찌 산쿄 가부시키가이샤 피리미딜 인돌린 화합물
EP2241558A1 (en) 2009-04-03 2010-10-20 Merck Serono SA Oxadiazole derivatives
TW201039827A (en) 2009-04-15 2010-11-16 Daiichi Sankyo Co Ltd Indoline compound
AU2010279964B2 (en) 2009-08-05 2016-02-11 Daiichi Sankyo Company, Limited Amide derivative
JP5546543B2 (ja) 2009-08-05 2014-07-09 第一三共株式会社 スルホン誘導体
SI2628733T1 (sl) * 2010-10-14 2015-10-30 Daiichi Sankyo Company, Limited Derivati acilbenzena
JP5973440B2 (ja) 2011-07-29 2016-08-23 第一三共株式会社 Ｎ−ヘテロ環置換アミド誘導体
MX2014008790A (es) 2012-01-18 2014-10-13 Daiichi Sankyo Co Ltd Derivado de fenilazol sustituido.

Also Published As

Publication number Publication date
AU2013210394A1 (en) 2014-08-14
ES2602962T3 (es) 2017-02-23
US20140357675A1 (en) 2014-12-04
TWI551590B (zh) 2016-10-01
EP2805941A1 (en) 2014-11-26
AU2013210394A2 (en) 2014-10-16
CA2861847A1 (en) 2013-07-25
EP3009433B1 (en) 2017-06-21
PH12014501646A1 (en) 2014-10-13
JP2017052800A (ja) 2017-03-16
HK1200824A1 (en) 2015-08-14
EP2805941B1 (en) 2016-08-17
EP2805941A4 (en) 2015-08-05
MX2014008790A (es) 2014-10-13
SG11201404026SA (en) 2014-11-27
IN2014MN01442A (pt) 2015-07-03
CO7020920A2 (es) 2014-08-11
RU2014133738A (ru) 2016-03-10
EP3009433A1 (en) 2016-04-20
US9233958B2 (en) 2016-01-12
TW201335141A (zh) 2013-09-01
KR20140113688A (ko) 2014-09-24
JPWO2013108800A1 (ja) 2015-05-11
WO2013108800A1 (ja) 2013-07-25
CN104159892A (zh) 2014-11-19
ES2640667T3 (es) 2017-11-03
ZA201405108B (en) 2015-10-28
IL233682A0 (en) 2014-09-30
JP6104181B2 (ja) 2017-03-29
US20160081993A1 (en) 2016-03-24
HK1220448A1 (zh) 2017-05-05
US20160090375A1 (en) 2016-03-31
US9725438B2 (en) 2017-08-08
NZ627303A (en) 2015-11-27

Similar Documents

Publication Publication Date Title
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112014010590A2 (pt) 18-metil-6,7-metilen-3-oxo-17-pregn-4-eno-21,17?-carbolactonas, preparações farmacêuticas contendo os compostos mencionados e seu uso na terapia da endometriose
BR112012011128A2 (pt) composição farmacêutica compreendendo um agonista de glp-1, uma insulina e uma metionina
BR112015001419A2 (pt) composto, composição farmacêutica, e, métodos para inibir romk em um paciente, para causar diurese, natriurese ou ambos e para tratamento de um ou mais distúrbios
BR112014017656A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0913291A2 (pt) composto, pró-droga, medicamento, métodos para diminuir a proteína 4 ou tratamento de diabete em um mamífero, e, uso do composto
BR112015032623A8 (pt) composto, composição farmacêutica, combinação, e, uso de um composto
BR112012006172A2 (pt) derivados de alqueno oxindol e seus usos para o tratamento de obesidade, diabetes e hiperlipidemia
BR112014032809A8 (pt) urolitinas, usos de uma quantidade eficaz de uma urolitina ou um sal farmaceuticamente aceitável da mesma e composição compreendendo as mesmas
BR112013024973A2 (pt) prevenção de hipoglicemia em pacientes com diabetes mellitus do tipo 2
BR112014030966A2 (pt) composto, composição farmacêutica, e, métodos para inibir serina protease, para inibir tripsina e enteropeptidase, para tratar hiperglicemia, para profilaxia ou tratamento da diabetes, para melhorar a sensibilidade à insulina e para profilaxia ou tratamento da obesidade, hiperlipidemia, uma complicação diabética ou síndrome metabólica
BR112014007257A2 (pt) composto, medicamento, métodos para inibir um colesterol 24-hidrolase em um mamífero e para a profilaxia ou tratamento de doença neurodegenerativa em um mamífero, e, uso do composto ou sal
WO2010095768A8 (en) 4 -isopropylphenyl glucitol compounds as sglt1 inhibitors
BR112014015845A2 (pt) derivados de azetidina, composições farmacêuticas e seu uso
BR112014017985A8 (pt) Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
PH12014502448A1 (en) Pharmaceutical combinations for the treatment of metabolic disorders
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
CL2009000757A1 (es) Compuestos derivados de 6,8,2´-tris-(isobut-2-en-1-il)-diosmetina; procedimientos para su elaboracion; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades venosas cronicas, sindrome post-trombotico, complicaciones vasculares ligadas a la diabetes, entre otras.
BR112018001035A2 (pt) compostos de fenoxiacetamidas aneladas, sal farmaceuticamente aceitável, seu método de síntese, combinação de medicamento e uso dos mesmos
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos
BR112013027486A2 (pt) combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor
BR112015022290A2 (pt) derivados de heterocíclicos benzo-fundidos úteis como agonistas de gpr120
BR112014032964A2 (pt) composto, composição farmacêutica, uso do composto, e, método para preparar o composto

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]